Linda Björkhem-Bergman
Om mig
Jag disputerade på Avd för Patologi, Institutionen för Laboratoriemedicin, 2004 med en avhandling om cancerutveckling och cytostatikaresistens. Jag började därefter som ST-läkare och post-doc inom Klinisk Farmakologi och uppnådde specialistkompetens i Klinisk Farmakologi 2012. Jag blev docent i Klinisk Farmakologi vid KI 2013 men började samma år arbete som läkare inom Palliativ Vård. Jag har numera min kliniska bas på Stockholms Sjukhem där jag är överläkare inom Palliativ Vård samt som vetenskaplig ledare vid Palliativt Kunskapscentrum (PKC) i Region Stockholm.
Jag startade min egen forskargrupp inom Palliativ Medicin på NVS, Avd för Klinisk Geriatrik i januari 2018. Forskargruppen består idag (2024) av 8 personer. Jag (forskargruppsledare), 3 doktorander och 4 post docs. Alla medarbetare i gruppen arbetar med forskning på deltid vid sidan av kliniskt arbete inom palliativ vård. Vi är 6 läkare, 1 sjuksköterska och 1 dietist i gruppen.
Sedan 1 okt 2024 är jag Professor i Palliativ Medicin vid Karolinska Institutet med förenad anställning som Överläkare på Stockhoms Sjukhem, Palliativ vård.
Min utbildning:
Läkarexamen, Karolinska Institutet, 2001 och leg läk 2006
PhD 2004, Karolinska Institutet
Docent 2013, Karolinska Institutet
Specialistläkare i klinisk farmakologi 2012 och i palliativ medicin 2021
Forskningsbeskrivning
Vår forskargrupp bedriver forskning inom Palliativ Medicin där vi har en ganska stor bredd på våra projekt som täcker flera olika områden i ämnet. Målet med vår forskning är att hitta nya behandlingar och strategier för att förbättra livskvalitén och minska symptombördan hos patienter som befinner sig i livets slutskede. Målet är också att ta fram mer evidensbaserad kunskap för vård och symptomlindring i livets slutskede, där det idag finns en del kunskapsluckor.
Vi bedriver främst kliniska studier där forskningsfrågeställningarna kommer från vårt dagliga kliniska arbete inom palliativ vård. Vi har även translationella och experimentella projekt i samarbete med flera olika forskargrupper på Institutionen för Laboratoriemedicin, KI.
Mitt huvudfokus har under senare år varit att undersöka möjliga positiva effekter av vitamin D-behandling till cancerpatienter och vitamin D's effekter på immunförsvaret. Vi har också projekt kring immunförsvarets funktion i livets slut, behandling och orsaker till cancerutlöst fatigue och prognostisering i palliativ vård. I forskargruppen har vi också projekt om behandling av malign ascites och utveckling av ultraljudsbehandling i palliativ hemsjukvård, olika aspekter på läkemedelsbehandling med fokus på könsskillnader och utsättning av läkemedel i livet slut, studier av alternativ- och komplementärmedicinska behandlingar (CAM), samt studier om nutritionsbehandling till cancerpatienter.
Undervisning
Vetenskaplig ledare vid Palliativt Kunskapscentrum (PKC) i Region Stockholm sedan 2022 vilket innebär regelbunden undervisning för personal inom palliativ vård (läkare, sjuksköterskor, undersköterskor, paramedicinare). Mitt huvudområde har framför allt varit symptomlindring och vård i livets absoluta slutskede.
Undervisar i palliativ medicin för läkare på grundutbildning och på specialistnivå.
Kursansvarig för två ST-läkarkurser i palliativ medicin inom geriatrik och invärtesmedicin (B5 och C5-kurs som ges via Palliativt Kunskapscentrum i Region Stockholm).
Undervisar i palliativ medicin för fysioterapeuter och arbetsterapeuter på grundutbildningen.
Huvudhandledare för ett 10-tal ST-läkare i deras vetenskapliga arbeten inom palliativ medicin och geriatrik.
Undervisar i vetenskapsmetodik för ST-läkare i geriatrik (2 dagars kurs 1 ggr / år).
Koordinator för läkarstudenternas exjobb 2014-2015.
Undervisat på grundutbildningen inom klinisk farmakologi för läkare, sjuksköterskor och biomedicinska analytiker (BMA). Handlett ett flertal BMA, biomedicinare och läkare i deras examensarbete.
Under 90-talet även undervisat i biokemi och patologi på läkarlinjen som amanuens.
Medförfattare i läroböcker:
"Palliativ medicin" i boken Klinisk Geriatrik (Libers förlag 2020)
"Palliativ cancervård" i böckerna Klinisk Omvårdnad 1 och 2 (Libers förlag, 2021)
”Vård i livets slut” i boken Boken om Demenssjukdomar (Libers förlag 2023)
Artiklar
- Journal article: GERONTOLOGY. 2025;:1-20Dahlén E; Hedman C; Mily A; Alisjahbana A; Spulber G; Holmström-Edstedt J; Bergman P; Buggert M; Björkhem-Bergman L
- Journal article: BMJ SUPPORTIVE & PALLIATIVE CARE. 2025;:spcare-2025-005618Bjorkhem-Bergman L; Fuerst P; Lundstrom S
- Article: LAKARTIDNINGEN. 2025;122:24129Eckerdal G; Lindberg J; Birr A; Björkhem-Bergman L; Rehnberg A-S; Gogineni M; Karlsson M; Schmitz L; Dettmann S
- Article: ISCIENCE. 2025;28(3):112082Olofsson A; Humbert M; Rekha RS; Frankling MH; Lund-Johansen F; Bergman P; Bjorkhem-Bergman L; Karlsson AC
- Article: BMJ SUPPORTIVE & PALLIATIVE CARE. 2024;15(1):141-148Klasson C; Helde Frankling M; Lundh Hagelin C; Bjorkhem-Bergman L; Alvariza A
- Article: JOURNAL OF GERIATRIC ONCOLOGY. 2024;15(8):102048Spulber G; Björkhem-Bergman L; Schultz T; Strang P
- Article: JOURNAL OF PALLIATIVE MEDICINE. 2024;28(1):35-41Fridegren J; Bjorkhem-Bergman L; Schultz T; Strang P
- Article: CURRENT ONCOLOGY. 2024;31(10):6205-6217Strang P; Petzold M; Bjorkhem-Bergman L; Schultz T
- Article: JOURNAL OF PALLIATIVE MEDICINE. 2024;27(10):1310-1317Frisk G; Szilcz M; Hedman C; Bjorkhem-Bergman L
- Article: THYROID. 2024;34(6):713-722Winter J; Axelsson E; Björkhem-Bergman L; Ihre Lundgren C; Hedman C
- Article: UPSALA JOURNAL OF MEDICAL SCIENCES. 2024;129(1):e10504Bjorkhem-Bergman L; Schultz T; Strang P
- Article: ACTA ONCOLOGICA. 2024;63:9-16Almerud A; Frisk G; Klasson C; Bjoerkhem-Bergman L
- Article: BMC PALLIATIVE CARE. 2023;22(1):159Goodrose-Flores C; Bonn SE; Klasson C; Frankling MH; Lagerros YT; Bjorkhem-Bergman L
- Journal article: JOURNAL OF IMMUNOLOGY. 2023;210(Supplement_1):75.20Olofsson A; Humbert M; Niessl J; Hodcroft E; Gao Y; Sohlberg E; Malmberg K-J; Lund-Johansen F; Björkhem-Bergman L; Jenmalm MC; Ljunggren H-G; Buggert M; Karlsson AC
- Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2023;120(12):e2220320120Humbert M; Olofsson A; Wullimann D; Niessl J; Hodcroft EB; Cai C; Gao Y; Sohlberg E; Dyrdak R; Mikaeloff F; Neogi U; Albert J; Malmberg K-J; Lund-Johansen F; Aleman S; Bjorkhem-Bergman L; Jenmalm MC; Ljunggren H-G; Buggert M; Karlsson AC
- Journal article: ACTA ONCOLOGICA. 2022;61(12):1435-1436Bjorkhem-Bergman L
- Article: BMJ SUPPORTIVE & PALLIATIVE CARE. 2022;12(3):332-338Goodrose-Flores C; Schedin A; Nelander J; Almerud A; Trolle-Lagerros Y; Bonn S; Bjorkhem-Bergman L
- Article: LIFE-BASEL. 2022;12(6):846Dahlen E; Bjorkhem-Bergman L
- Article: LIFE-BASEL. 2022;12(5):671Goodrose-Flores C; Bonn S; Klasson C; Frankling MH; Lagerros YT; Bjorkhem-Bergman L
- Article: LIFE-BASEL. 2022;12(4):525Frisk G; Frankling MH; Warnqvist A; Bjorkhem-Bergman L; Hedman M
- Article: LIFE-BASEL. 2022;12(2):298Camartin C; Bjorkhem-Bergman L
- Article: CANCERS. 2022;14(3):746Klasson C; Helde Frankling M; Warnqvist A; Sandberg C; Nordstroem M; Lundh-Hagelin C; Bjoerkhem-Bergman L
- Article: NUTRIENTS. 2022;14(3):602Helde Frankling M; Klasson C; Bjoerkhem-Bergman L
- Article: LIFE-BASEL. 2022;12(1):105Goodrose-Flores C; Eke H; Bonn SE; Bjoerkhem-Bergman L; Trolle Lagerros Y
- Article: PHARMACOLOGY RESEARCH & PERSPECTIVES. 2021;9(6):e00884Bergstrom H; Lindahl A; Warnqvist A; Diczfalusy U; Ekstrom L; Bjorkhem-Bergman L
- Article: LIFE-BASEL. 2021;11(11):1233Helde Frankling M; Klasson C; Bjorkhem-Bergman L
- Article: CANCERS. 2021;13(18):4689Bergstrom H; Frankling MH; Klasson C; Sandblom AL; Diczfalusy U; Bjorkhem-Bergman L
- Article: INFECTIOUS DISEASES. 2021;53(9):719-723Ranch-Lundin M; Schedin A; Bjorkhem-Bergman L
- Article: CANCERS. 2021;13(15):3707Frankling MH; Klasson C; Sandberg C; Nordstrom M; Warnqvist A; Bergqvist J; Bergman P; Bjorkhem-Bergman L
- Article: BMC WOMENS HEALTH. 2021;21(1):166Bergstrom H; Ekstrom L; Warnqvist A; Bergman P; Bjorkhem-Bergman L
- Article: PHARMACEUTICALS. 2021;14(4):368Frisk G; Bergstrom H; Frankling MH; Bjorkhem-Bergman L
- Article: DRUG TESTING AND ANALYSIS. 2021;13(3):550-557Schulze J; Suominen T; Bergstrom H; Ericsson M; Bjorkhem Bergman L; Ekstrom L
- Article: JOURNAL OF PALLIATIVE MEDICINE. 2021;24(3):433-437Klasson C; Helde-Frankling M; Sandberg C; Nordstrom M; Lundh-Hagelin C; Bjorkhem-Bergman L
- Article: BMJ SUPPORTIVE & PALLIATIVE CARE. 2020;14(E2):bmjspcare-2020-002331-e1850Schedin A; Goodrose-Flores C; Bonn S; Bjorkhem-Bergman L
- Article: DRUG TESTING AND ANALYSIS. 2020;12(9):1229-1240Mullen J; Baekken L; Bergstrom H; Bjorkhem Bergman L; Ericsson M; Ekstrom L
- Article: NUTRIENTS. 2020;12(5):E1230-1230Frankling MH; Norlin A-C; Hansen S; Borgstrom EW; Bergman P; Bjorkhem-Bergman L
- Article: BMC PALLIATIVE CARE. 2019;18(1):80Sterpu B; Lindman P; Bjorkhem-Bergman L
- Article: BMJ SUPPORTIVE & PALLIATIVE CARE. 2019;14(E1):bmjspcare-2019-001932-e352Rasch-Westin M; Helde-Frankling M; Bjorkhem-Bergman L
- Article: ENDOCRINE CONNECTIONS. 2019;8(7):1070-1081Saini A; Bjorkhem-Bergman L; Bostrom J; Lilja M; Melin M; Olsson K; Ekstrom L; Bergman P; Altun M; Rullman E; Gustafsson T
- Article: BIOLOGY OF SEX DIFFERENCES. 2018;9(1):47Bergstrom H; Branvall E; Helde-Frankling M; Bjorkhem-Bergman L
- Article: EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 2018;37(9):1735-1744Bjorkhem-Bergman L; Missailidis C; Karlsson-Valik J; Tammelin A; Ekstrom L; Bottai M; Hammar U; Lindh G; Bergman P
- Article: BMC RESEARCH NOTES. 2018;11(1):619Björkhem-Bergman L; Torefalk E; Ekström L; Bergman P
- Article: BMJ SUPPORTIVE & PALLIATIVE CARE. 2018;8(1):30-33Pedersen K; Bjorkhem-Bergman L
- Article: BMC RESEARCH NOTES. 2018;11(1):51Björkhem-Bergman L; Lehtihet M; Rane A; Ekström L
- Article: BMJ SUPPORTIVE & PALLIATIVE CARE. 2017;7(4):458-463Helde-Frankling M; Bergqvist J; Klasson C; Nordstrom M; Hoijer J; Bergman P; Bjorkhem-Bergman L
- Article: PLOS ONE. 2017;12(8):e0184208Helde-Frankling M; Hoijer J; Bergqvist J; Bjorkhem-Bergman L
- Article: VACCINE. 2017;35(20):2654-2660Zangenah S; Bjorkhem-Bergman L; Norlin A-C; Hansen S; Lindqvist L; Henriques-Normark B; Bergman P
- Article: HORMONE AND METABOLIC RESEARCH. 2016;48(12):834-839Ekstrom L; Storbjork L; Bjorkhem-Bergman L
- Article: PLOS ONE. 2016;11(9):e0163451Norlin A-C; Hansen S; Wahren-Borgstrom E; Granert C; Bjorkhem-Bergman L; Bergman P
- Article: CANCERS. 2016;8(9):84Helde-Frankling M; Bergqvist J; Bergman P; Bjorkhem-Bergman L
- Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2016;118(6):499-502Bjorkhem-Bergman L; Nylen H; Eriksson M; Parini P; Diczfalusy U
- Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2016;118(3):214-218Ovesjo M-L; Skilving I; Bergman P; Rane A; Ekstrom L; Bjorkhem-Bergman L
- Article: PHARMACOLOGY RESEARCH & PERSPECTIVES. 2015;3(6):e00192Ekstrom L; Skilving I; Ovesjo M-L; Aklillu E; Nylen H; Rane A; Diczfalusy U; Bjorkhem-Bergman L
- Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2015;117(4):261-266Betts S; Bjorkhem-Bergman L; Rane A; Ekstrom L
- Article: BMC RESEARCH NOTES. 2015;8:498Bergman P; Norlin A-C; Hansen S; Björkhem-Bergman L
- Article: BMC RESEARCH NOTES. 2015;8:391Bergman P; Norlin A-C; Hansen S; Björkhem-Bergman L
- Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2015;117(2):133-136Skilving I; Acimovic J; Rane A; Ovesjo M-L; Bjoerkhem-Bergman L
- Article: FORENSIC SCIENCE INTERNATIONAL. 2015;252:150-156Andersson M; Bjorkhem-Bergman L; Beck O
- Article: PLOS ONE. 2015;10(5):e0128223Bergman P; Sperneder S; Hoijer J; Bergqvist J; Bjorkhem-Bergman L
- Article: JOURNAL OF PALLIATIVE CARE. 2015;31(3):172-176Is There a Role for Statins in Palliative Care for Patients Suffering from Hepatocellular Carcinoma?Bjorkhem-Bergman L
- Article: SUBSTANCE ABUSE AND REHABILITATION. 2014;5:121-127Garevik N; Rane A; Bjorkhem-Bergman L; Ekstrom L
- Article: PHARMACOLOGY RESEARCH & PERSPECTIVES. 2014;2(6):e00071Andersson M; Bjorkhem-Bergman L; Ekstrom L; Bergqvist L; Lagercrantz H; Rane A; Beck O
- Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2014;115(4):366-371Nylen H; Bjorkhem-Bergman L; Ekstrom L; Roh H-K; Bertilsson L; Eliasson E; Lindh JD; Diczfalusy U
- Article: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2014;23(10):1101-1106Bjorkhem-Bergman L; Backheden M; Lofdal KS
- Journal article: JOURNAL OF HORMONES. 2014;2014(1):1-7Mullen JE; Gårevik N; Schulze JJ; Rane A; Bergman LB; Ekström L
- Article: DRUG METABOLISM AND PHARMACOKINETICS. 2014;29(4):352-355Quinine Compared to 4β-Hydroxycholesterol and Midazolam as Markers for CYP3A Induction by RifampicinBjorkhem-Bergman L; Backstrom T; Nylen H; Ronquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U
- Article: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. 2014;44(2):125-130Rashid M-U; Dalhoff A; Backstrom T; Bjorkhem-Bergman L; Panagiotidis G; Weintraub A; Nord CE
- Article: FEBS OPEN BIO. 2014;4:886-891Bjorkhem-Bergman L; Johansson M; Morgenstern R; Rane A; Ekstrom L
- Article: DRUG METABOLISM AND DISPOSITION. 2013;41(9):1610-1615Bjorkhem-Bergman L; Bergstrom H; Johansson M; Parini P; Eriksson M; Rane A; Ekstrom L
- Article: LAKARTIDNINGEN. 2013;110(32-33):1409-1411Björkhem-Bergman L; Wallin C
- Article: DRUG METABOLISM AND DISPOSITION. 2013;41(8):1488-1493Bjorkhem-Bergman L; Backstrom T; Nylen H; Ronquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U
- Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2013;69:73-78Bjorkhem-Bergman L; Andersen-Karlsson E; Laing R; Diogene E; Melien O; Jirlow M; Malmstrom RE; Vogler S; Godman B; Gustafsson LL
- Article: DRUG METABOLISM AND DISPOSITION. 2013;41(4):704-708Bjorkhem-Bergman L; Nylen H; Norlin A-C; Lindh JD; Ekstrom L; Eliasson E; Bergman P; Diczfalusy U
- Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2013;430(1):90-94Ekstrom L; Johansson M; Monostory K; Rundlof A-K; Arner ESJ; Bjorkhem-Bergman L
- Article: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2013;61(1):1-7Skogastierna C; Bjorkhem-Bergman L; Bergman P; Eliasson E; Rane A; Ekstrom L
- Article: PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES. 2012;11(12):1797-1801Lindh JD; Bjorkhem-Bergman L; Eliasson E
- Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2012;425(2):348-352Acimovic J; Lovgren-Sandblom A; Eriksson LC; Bjorkhem-Bergman L
- Article: HEPATOLOGY. 2012;55(4):1112-1121Rohr-Udilova N; Sieghart W; Eferl R; Stoiber D; Bjorkhem-Bergman L; Eriksson LC; Stolze K; Hayden H; Keppler B; Sagmeister S; Grasl-Kraupp B; Schulte-Hermann R; Peck-Radosavljevic M
- Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2012;417(3):1046-1051Skogastierna C; Johansson M; Parini P; Eriksson M; Eriksson LC; Ekstrom L; Bjorkhem-Bergman L
- Article: BMJ OPEN. 2012;2(6):e001663Bergman P; Norlin A-C; Hansen S; Rekha RS; Agerberth B; Bjorkhem-Bergman L; Ekstrom L; Lindh JD; Andersson J
- Article: LAKARTIDNINGEN. 2011;108(48):2512Björkhem Bergman L; Böttiger Y
- Article: PLOS ONE. 2011;6(8):e24394Bergman P; Linde C; Putsep K; Pohanka A; Normark S; Henriques-Normark B; Andersson J; Bjorkhem-Bergman L
- Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2011;72(1):153-156Andersson ML; Bjorkhem-Bergman L; Lindh JD
- Journal article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2011;72(1):164-165Bjorkhem-Bergman L; Lindh JD; Bergman P
- Article: DRUG METABOLISM AND DISPOSITION. 2011;39(5):933-937Lindh JD; Andersson ML; Eliasson E; Bjorkhem-Bergman L
- Article: LAKARTIDNINGEN. 2010;107(46):2900-2901Björkhem Bergman L; Böttiger Y
- Article: ANTICANCER RESEARCH. 2010;30(4):1105-1112Bjorkhem-Bergman L; Acimovic J; Torndal U-B; Parini P; Eriksson LC
- Article: JOURNAL OF LIPID RESEARCH. 2010;51(2):318-323Shafaati M; Mast N; Beck O; Nayef R; Heo GY; Bjorkhem-Bergman L; Luetjohann D; Bjorkhem I; Pikuleva IA
- Article: LAKARTIDNINGEN. 2008;105(42):2942Björkhem Bergman L; Lindh J
- Article: LAKARTIDNINGEN. 2008;105(19):1398-1399Björkhem Bergman L; Josephson F
- Article: BIOCHEMICAL PHARMACOLOGY. 2005;69(12):1765-1772Madeja Z; Sroka J; Nyström C; Björkhem-Bergman L; Nordman T; Damdimopoulos A; Nalvarte I; Eriksson LC; Spyrou G; Olsson JM; Björnstedt M
- Article: CARCINOGENESIS. 2005;26(1):125-131Björkhem-Bergman L; Torndal UB; Eken S; Nyström C; Capitanio A; Larsen EH; Björnstedt M; Eriksson LC
- Article: PEPTIDES. 2004;25(11):1849-1855Björkhem-Bergman L; Jönsson-Videsäter K; Paul C; Björnstedt M; Andersson M
- Article: HISTORY OF PSYCHIATRY. 2004;15(58 Pt 2):193-200Stolt C-M; Björkhem-Bergen L
- Article: BIOCHEMICAL PHARMACOLOGY. 2004;67(3):513-522Jönsson-Videsäter K; Björkhem-Bergman L; Hossain A; Söderberg A; Eriksson LC; Paul C; Rosén A; Björnstedt M
- Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2003;278(4):2141-2146Xia L; Nordman T; Olsson JM; Damdimopoulos A; Björkhem-Bergman L; Nalvarte I; Eriksson LC; Arnér ESJ; Spyrou G; Björnstedt M
- Article: BIOCHEMICAL PHARMACOLOGY. 2002;63(10):1875-1884Björkhem-Bergman L; Jönsson K; Eriksson LC; Olsson JM; Lehmann S; Paul C; Björnstedt M
- Article: JOURNAL OF HEPATOLOGY. 2001;35(2):259-264Björkhem L; Teclebrhan H; Kesen E; Olsson JM; Eriksson LC; Björnstedt M
- Visa fler
Alla övriga publikationer
- Conference publication: JOURNAL OF IMMUNOLOGY. 2023;210(1)Olofsson A; Humbert M; Niessl J; Hodcroft E; Gao Y; Sohlberg E; Malmberg K-J; Lund-Johansen F; Bjorkhem-Bergman L; Jenmalm MC; Ljunggren H-G; Buggert M; Karlsson AC
- Review: LIFE-BASEL. 2022;12(5):613Hedman C; Frisk G; Bjorkhem-Bergman L
- Preprint: BIORXIV. 2021Bergström H; Heiland C; Björkhem-Bergman L; Ekström L
- Review: CANCERS. 2021;13(5):985Klasson C; Helde Frankling M; Lundh Hagelin C; Bjorkhem-Bergman L
- Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2017;18(10):2170Helde-Frankling M; Bjorkhem-Bergman L
- Review: BMJ SUPPORTIVE & PALLIATIVE CARE. 2016;6(3):287-291Bjorkhem-Bergman L; Bergman P
- Review: EXPERT REVIEW OF ANTI-INFECTIVE THERAPY. 2013;11(12):1391-1400Bergman PW; Bjorkhem-Bergman L
- Conference publication: THERAPEUTIC DRUG MONITORING. 2013;35(5):728Andersson M; Bjorkhem-Bergman L; Beck O
- Review: PLOS ONE. 2013;8(6):e65835Bergman P; Lindh AU; Bjorkhem-Bergman L; Lindh JD
- Review: IN VIVO. 2012;26(4):527-535Bjorkhem-Bergman L; Ekstrom L; Eriksson LC
- Conference publication: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2011;109:153-154Lindh JD; Andersson ML; Eliasson E; Bjorkhem-Bergman L
- Conference publication: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2011;109:40-41Andersson ML; Bjorkhem-Bergman L; Lindh JD
- Review: JOURNAL OF PSYCHOPHARMACOLOGY. 2011;25(3):299-305Bjorkhem-Bergman L; Asplund AB; Lindh JD
- Review: PLOS ONE. 2010;5(5):e10702Bjorkhem-Bergman L; Bergman P; Andersson J; Lindh JD
- Review: LAKARTIDNINGEN. 2009;106(26-27):1746-1747Björkhem Bergman L; Böttiger Y
- Doctoral thesis: 2004Björkhem Bergman L
- Published conference paper: BIOFACTORS. 2003;18(1-4):45-50Nordman T; Xia L; Björkhem-Bergman L; Damdimopoulos A; Nalvarte I; Arnér ESJ; Spyrou G; Eriksson LC; Björnstedt M; Olsson JM
- Corrigendum: BIOCHEMICAL PHARMACOLOGY. 2002;64(1):159Björkhem-Bergman L; Jönsson K; Eriksson LC; Olsson JM; Lehmann S; Paul C; Björnstedt M
- Review: BIOMEDICAL AND ENVIRONMENTAL SCIENCES. 1997;10(2-3):271-279Björnstedt M; Kumar S; Björkhem L; Spyrou G; Holmgren A
Forskningsbidrag
- To live until death - Factors affecting symptom distress, quality of life and survival time in cancer patients in palliative stages. Focus on vitamin D and the immune system.Swedish Cancer Society1 January 2018In palliative care, all treatment aims at alleviating symptoms and maintaining as high a quality of life as possible despite a life-threatening illness. The goal is "to live until you die". Infections, pain and fatigue are common among palliative patients and often lead to lower quality of life during their last life. Vitamin D is a hormone that is important for a healthy immune system and deficiency can lead to increased risk of infections, more pain, fatigue and depression. In a small pilot study, we saw that vitamin D treatment led to reduced pain and fewer infections in our cancer patients without giving any side effects. We now want to do a large clinical trial in which 254 patients with incurable cancer are treated with either vitamin D or placebo for 12 weeks. The purpose is to investigate whether vitamin D can reduce pain, reduce infections and fatigue and improve quality of life. The mechanisms behind vitamin D's effects on pain and inflammation in the body will also be studied. In the study, we also evaluate new and old biomarkers in order to better predict the survival time In a separate study, we will study the immune system's function in the end of life in 100 cancer patients and examine the relationship with immune responses and vitamin D levels. Today, there are no guidelines for supplementation of vitamin D to cancer patients, leaving the field open for thought-provoking and unfounded statements about benefits and risks. Therefore, proper studies are needed, as suggested here. If vitamin D treatment can reduce the burden of infection, fatigue and / or pain in palliative patients, this is of great importance to health care as it can reduce patient suffering, reduce drug treatment and reduce the weight of care. In the event of a negative result, we know that we do not need to treat vitamin D deficiency in our cancer patients, ie even a negative result is important.
- Can treatment with vitamin D for palliative cancer patients reduce the burden of infection and pain and increase the quality of life?Swedish Cancer Society1 January 2017Infections and pain are a major problem in patients with incurable cancer. In a recent study on palliative cancer patients, we have seen that the patients had very low vitamin D levels. Vitamin D is needed for a healthy immune system. We have previously shown that vitamin D treatment reduced the burden of infection in patients with immunodeficiency disease. In our cancer patients, we also saw a connection between pain medication and vitamin D levels. The lower the vitamin D value, the more pain treatment. Other researchers have shown that low levels of vitamin D are associated with increased pain sensitivity and greater risk of depression. Our goal is to investigate whether we can reduce the burden of infection, reduce pain and improve the quality of life of palliative cancer patients with the help of vitamin D treatment in a gentle and non-adverse manner. We therefore want to do a study in which we treat these patients with vitamin D and follow them for the burden of infection, pain management and self-rated quality of life. A positive result in these studies would mean new opportunities for an almost non-adverse treatment that could improve and perhaps prolong the last time in life for patients with incurable cancer. Even a negative result is interesting as there is currently no knowledge of vitamin D treatment that benefits this patient group.
- Can treatment with vitamin D for palliative cancer patients reduce the burden of infection and pain and increase the quality of life?Swedish Cancer Society1 January 2016Infections and pain are a major problem in patients with incurable cancer. In a recent study on palliative cancer patients, we have seen that the patients had very low vitamin D levels. Vitamin D is needed for a healthy immune system. We have previously shown that vitamin D treatment reduced the burden of infection in patients with immunodeficiency disease. In our cancer patients, we also saw a connection between pain medication and vitamin D levels. The lower the vitamin D value, the more pain treatment. Other researchers have shown that low levels of vitamin D are associated with increased pain sensitivity and greater risk of depression. Our goal is to investigate whether we can reduce the burden of infection, reduce pain and improve the quality of life of palliative cancer patients with the help of vitamin D treatment in a gentle and non-adverse manner. We therefore want to do a study in which we treat these patients with vitamin D and follow them for the burden of infection, pain management and self-rated quality of life. A positive result in these studies would mean new opportunities for an almost non-adverse treatment that could improve and perhaps prolong the last time in life for patients with incurable cancer. Even a negative result is interesting as there is currently no knowledge of vitamin D treatment that benefits this patient group.
- Can treatment with vitamin D for palliative cancer patients reduce the burden of infection and pain and increase the quality of life?Swedish Cancer Society1 January 2015Infections and pain are a major problem in patients with incurable cancer. In a recent study on palliative cancer patients, we have seen that the patients had very low vitamin D levels. Vitamin D is needed for a healthy immune system. We have previously shown that vitamin D treatment reduced the burden of infection in patients with immunodeficiency disease. In our cancer patients, we also saw a connection between pain medication and vitamin D levels. The lower the vitamin D value, the more pain treatment. Other researchers have shown that low levels of vitamin D are associated with increased pain sensitivity and greater risk of depression. Our goal is to investigate whether we can reduce the burden of infection, reduce pain and improve the quality of life of palliative cancer patients with the help of vitamin D treatment in a gentle and non-adverse manner. We therefore want to do a study in which we treat these patients with vitamin D and follow them for the burden of infection, pain management and self-rated quality of life. A positive result in these studies would mean new opportunities for an almost non-adverse treatment that could improve and perhaps prolong the last time in life for patients with incurable cancer. Even a negative result is interesting as there is currently no knowledge of vitamin D treatment that benefits this patient group.
Anställningar
- Professor/Överläkare, Neurobiologi, vårdvetenskap och samhälle, Karolinska Institutet, 2024-
- Senior Forskare, Neurobiologi, vårdvetenskap och samhälle, Karolinska Institutet, 2022-2024
- Forskare, Neurobiologi, vårdvetenskap och samhälle, Karolinska Institutet, 2018-2022
- Forskare, Laboratoriemedicin, Karolinska Institutet, 2015-2018
Examina och utbildning
- Docent, klinisk farmakologi, Karolinska Institutet, 2013
- MEDICINE DOKTORSEXAMEN, Institutionen för laboratoriemedicin, Karolinska Institutet, 2004
- Läkarexamen, Karolinska Institutet, 2001